E-LIB Suche - Ergebnisse für: Yardley, Denise A.

1

HER2 heterogeneity and treatment response–associated profil..:

Li, Zheqi ; Metzger Filho, Otto ; Viale, Giuseppe...
Journal of Clinical Investigation. 134 (2024) 7 - p. , 2024

Link: https://doi.org/10.1172/..

2

Neoadjuvant palbociclib plus either giredestrant or anastro..:

Hurvitz, Sara A ; Bardia, Aditya ; Quiroga, Vanesa...
The Lancet Oncology. 24 (2023) 9 - p. 1029-1041 , 2023

Link: https://doi.org/10.1016/..

3

Matching-adjusted indirect comparison of PFS and OS compari..:

Jhaveri, Komal ; O'Shaughnessy, Joyce ; Fasching, Peter A....
Therapeutic Advances in Medical Oncology. 15 (2023) - p. , 2023

Link: https://doi.org/10.1177/..

4

Intrinsic Subtype and Overall Survival of Patients with Adv..:

Prat, Aleix ; Solovieff, Nadia ; André, Fabrice...
Clinical Cancer Research. 30 (2023) 4 - p. 793-802 , 2023

Link: https://doi.org/10.1158/..

5

Rationale and trial design of NATALEE: a Phase III trial of..:

Slamon, Dennis J. ; Fasching, Peter A. ; Hurvitz, Sara...
Therapeutic Advances in Medical Oncology. 15 (2023) - p. , 2023

Link: https://doi.org/10.1177/..

6

Correlation between work productivity loss and EORTC QLQ-C3..:

Tripathy, Debu ; Curteis, Tristan ; Hurvitz, Sara...
Therapeutic Advances in Medical Oncology. 14 (2022) - p. 175883592210812 , 2022

Link: https://doi.org/10.1177/..

7

Treatment discontinuation, patient-reported toxicities and ..:

Sella, Tal ; Zheng, Yue ; Tayob, Nabihah...
npj Breast Cancer. 8 (2022) 1 - p. , 2022

Link: https://doi.org/10.1038/..

8

A Phase II Study Evaluating Orteronel, an Inhibitor of Andr..:

Yardley, Denise A. ; Young, Robyn R. ; Adelson, Kerin B....
Clinical Breast Cancer. 22 (2022) 3 - p. 269-278 , 2022

Link: https://doi.org/10.1016/..

9

Cardiac outcomes of subjects on adjuvant trastuzumab emtans..:

Barroso-Sousa, Romualdo ; Tarantino, Paolo ; Tayob, Nabihah...
npj Breast Cancer. 8 (2022) 1 - p. , 2022

Link: https://doi.org/10.1038/..

10

Baseline characteristics and first-line treatment patterns ..:

Kaufman, Peter A. ; Hurvitz, Sara A. ; O'Shaughnessy, Joyce...
Breast Cancer Research and Treatment. 188 (2021) 1 - p. 179-190 , 2021

Link: https://doi.org/10.1007/..

11

Safety and impact of dose reductions on efficacy in the ran..:

Burris, Howard A. ; Chan, Arlene ; Bardia, Aditya...
British Journal of Cancer. 125 (2021) 5 - p. 679-686 , 2021

Link: https://doi.org/10.1038/..

12

Glembatumumab vedotin for patients with metastatic, gpNMB o..:

Vahdat, Linda T. ; Schmid, Peter ; Forero-Torres, Andres...
npj Breast Cancer. 7 (2021) 1 - p. , 2021

Link: https://doi.org/10.1038/..

13

Chemotherapy-related amenorrhea (CRA) after adjuvant ado-tr..:

Ruddy, Kathryn J. ; Zheng, Yue ; Tayob, Nabihah...
Breast Cancer Research and Treatment. 189 (2021) 1 - p. 103-110 , 2021

Link: https://doi.org/10.1007/..

14

A window-of-opportunity trial of the CXCR1/2 inhibitor repa..:

Goldstein, Lori J. ; Perez, Raymond P. ; Yardley, Denise...
Breast Cancer Research. 22 (2020) 1 - p. , 2020

Link: https://doi.org/10.1186/..

15

Phase II trial of eribulin in patients who do not achieve p..:

Yardley, Denise A. ; Peacock, Nancy ; Daniel, Brooke...
Breast Cancer Research and Treatment. 180 (2020) 3 - p. 647-655 , 2020

Link: https://doi.org/10.1007/..